Search

Your search keyword '"Gong, Jianlin"' showing total 3 results
Start Over Author "Gong, Jianlin" Search Limiters Peer Reviewed Journal oncoimmunology
3 results on '"Gong, Jianlin"'

1. Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions.

Author

Shigeo Koido, Sadamu Homma, Masato Okamoto, Yoshihisa Namiki, Kazuki Takakura, Kan Uchiyama, Mikio Kajihara, Seiji Arihiro, Hiroo Imazu, Hiroshi arakawa, Shin Kan, Hideo Komita, Yuko Kamata, Masaki Ito, Toshifumi Ohkusa, Gong, Jianlin, and Hisao Tajiri

Subjects
*ANTINEOPLASTIC agents, *DENDRITIC cells, *CELL fusion, *TUMOR antigens, *CYTOTOXIC T cells, *MESSENGER RNA
Abstract

The rationale for fusing dendritic cells (DCs) with whole tumor cells to generate anticancer vaccines resides in the fact that the former operate as potent antigen-presenting cells, whereas the latter express a constellation of tumor-associated antigens (TAAs). although the administration of DC/malignant cell fusions to cancer patients is safe and this immunotherapeutic intervention triggers efficient tumor-specific T-cell responses in vitro, a limited number of objective clinical responses to DC/cancer cell fusions has been reported thus far. This review discusses novel approaches to improve the immunogenicity of DC/malignant cell fusions as anticancer vaccines. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

2. The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions.

Author

Shigeo Koido, Sadamu Homma, Masato Okamoto, Yoshihisa Namiki, Kazuki Takakura, Kan Uchiyama, Mikio Kajihara, Toshifumi Ohkusa, Gong, Jianlin, and Hisao Tajiri

Subjects
*CHEMICAL agonists, *DENDRITIC cells, *CANCER cells, *IMMUNE response, *IMMUNOSUPPRESSIVE agents
Abstract

The induction of antitumor immune responses by dendritic cell (DC)/tumor cell fusions can be modulated by their activation status. Our recent work reveals that the combination of toll-like receptor 2 (TLR2) and TLR4 agonists promotes the immunogenicity of DC/tumor cell fusions, allowing them to overcome the immunosuppressive efects of transforming growth factor β1. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

3. Chemoimmunotherapy targeting Wilms’ tumor 1 (WT1)-specific cytotoxic T lymphocyte and helper T cell responses for patients with pancreatic cancer.

Author

Koido, Shigeo, Homma, Sadamu, Okamoto, Masato, Takakura, Kazuki, Gong, Jianlin, Sugiyama, Haruo, Ohkusa, Toshifumi, and Tajiri, Hisao

Subjects
*PANCREATIC cancer, *T cells, *IMMUNOTHERAPY, *DENDRITIC cells, *EPITOPES, *CANCER chemotherapy
Abstract

We designed a phase 1 study using dendritic cells (DCs) pulsed with a mixture of three types of Wilms’ tumor 1 (WT1) peptides, including MHC class I/II restricted epitopes (DC/WT1-I/II). Our recent work reveals that the combination of DC/WT1-I/II and chemotherapy induced long-term WT1-specific CD4+and CD8+T cell responses. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results